CD274 and non-small cell lung carcinoma: It should also be noted that a recent study which did consider treatment costs in its cost‐effectiveness model found ATZ to be cost‐effective versus BSC for the adjuvant treatment of patients with resected PD‐L1+ stage II‐IIIA NSCLC, further supporting utilization of this regimen as the new standard of care in this setting.26